Results 231 to 240 of about 179,392 (293)

A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19. [PDF]

Adv Respir Med
Li R, Zhang J, Ren L.
europepmc   +1 more source

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler, Klara R. Klein, Ildiko Lingvay, Anthony Pick, Liana K. Billings   +4 more
wiley   +1 more source

Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. [PDF]

Clin Genitourin Cancer
Skelton WP, Masur J, Thomas J, Fallah P, Jain RK, Ravi P, Mantia C, McGregor BA, Nuzzo PV, Adib E, Zarif TE, Preston MA, Clinton TN, Li R, Steele GS, Kassouf W, Freeman D, Pond GR, Jain RK, Sonpavde GP.   +19 more
europepmc   +1 more source

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

A network meta-analysis comparative the efficacy of angiotensin-converting enzyme inhibitors and calcium channel blockers in hypertension. [PDF]

Medicine (Baltimore)
Yao YJ, Gui M, Cai SK.
europepmc   +1 more source

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney, Peter Rossing, Maria Eugenia Canziani, Maria Luiza Caramori, Ricardo Correa‐Rotter, Lisa Cronin, Christian Hugo, Bo Ji, Juliane Meyerhoff, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Shimoli V. Shah, Dick de Zeeuw, Katherine R. Tuttle   +14 more
wiley   +1 more source

Comparative safety and effectiveness of angiotensin converting enzyme inhibitors and thiazides and thiazide-like diuretics under strict monotherapy. [PDF]

J Clin Hypertens (Greenwich)
Anand TV, Bu F, Schuemie MJ, Suchard MA, Hripcsak G.   +4 more
europepmc   +1 more source

The Potential Role of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in Reducing Pneumonia Severity in Older Adults. [PDF]

Cureus
Thomas H, Yoshimatsu Y, Thompson T, Smithard DG.   +3 more
europepmc   +1 more source

The association between the use of angiotensin-converting enzyme inhibitors /angiotensin receptor blockers and the development of ventilator-associated pneumonia in the intensive care unit: a retrospective cohort study. [PDF]

BMC Pulm Med
Cai H, Shen H, Cao X.
europepmc   +1 more source

Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes. [PDF]

Kidney Int Rep
Chen JJ, Lee CC, Yen CL, Fan PC, Chan MJ, Tsai TY, Chen YC, Yang CW, Chang CH.   +8 more
europepmc   +1 more source